Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma

Table 1 Histologic types and Human epidermal growth factor receptor 2 protein expression in mixed gastric carcinoma

Type	No. of cases	Immunohistochemistry
			-	1+	2+	3+	Positive, n (%)
Mixed adenocarcinoma	216	Extensive		13	10	8	31 (14.4)
		Partial		21	15	14	50 (23.1)
		Focal		7	5	3	15 (6.9)
		Negative	120
Adenosquamous carcinoma	34	Extensive		0	1	0	1 (2.9)
		Partial		2	2	1	5 (14.7)
		Focal		2	0	1	3 (8.8)
		Negative	25
Mixed adenocarcinoma and neuroendocrine carcinoma	22	Extensive		0	0	0	0 (0.0)
		Partial		2	2	0	4 (18.2)
		Focal		1	1	1	3 (13.6)
		Negative	15
Mixed adenocarcinoma, squamous cell carcinoma and neuroendocrine carcinoma	5	Extensive		0	0	0	0 (0.0)
		Partial		1	0	0	1 (20.0)
		Focal		0	1	0	1 (20.0)
		Negative	3
Total	277		163 (58.8)	49 (17.7)	37 (13.4)	28 (10.1)	114 (41.2)

Table 2 Human epidermal growth factor receptor 2 positive staining intensity and range distribution in mixed gastric carcinoma n (%)

	Extensive	Partial	Focal	Value
Single-staining range	10	23	9	42 (36.8)
Multi-staining intensity	22	37	13	72 (63.2)
Total	32 (11.6)	60 (21.7)	22 (7.9)	114 (41.2)

Table 3 Human epidermal growth factor receptor 2 protein expression and gene amplification results

Staining intensity (No. of cases)	HER2 protein expression		HER2 amplification
	Staining Range	No. of cases	Cluster	Large granule	Dot	HH-17
3+ (28)	Extensive	8	3	2	2	1
	Partial	15	4	3	5	2
	Focal	5	2	1	0	0
2+ (37)	Extensive	11	3	2	2	1
	Partial	19	3	2	1	1
	Focal	7	1	1	0	0
1+ (49)	Extensive	13	1	1	0	1
	Partial	26	0	0	1	1
	Focal	10	0	0	0	0
Total		114	17	12	11	7

HH-17: Hyperhexasomy 17.

Table 4 Human epidermal growth factor receptor 2 amplification status and survival analyses

Treatment	HER2 amplification	No. of cases	Survival analysis (mo)
			Median PFS	Median OS
Chemotherapy alone	Cluster	7	6.3	11.9
	Large granule	6	5.8	12.2
	Dot	4	5.3	11.6
	HH-17	2	5.1	12.7
Trastuzumab combined with chemotherapy	Cluster	9	10.7	18.1
	Large granule	6	9.9	17.7
	Dot	5	8.3	16.5
	HH-17	2	7.6	14.3

HH-17: Hyperhexasomy 17; OS: Overall survival; PFS: Progression-free survival; HER2: Human epidermal growth factor receptor 2.

Table 5 Summary of survival analyses

Treatment	No. of cases	Survival analysis
		Median PFS (mo)	P value	Median OS (mo)	P value
Chemotherapy alone	19	5.6	0.01	12.1	0.01
Trastuzumab combined with chemotherapy	22	9.1		16.7

OS: Overall survival; PFS: Progression-free survival.